NRAS and cutaneous melanoma: In the cutaneous melanoma cohort, the PFS for NRAS mutant and wild-type patients were 2.7 months (95%CI: 1.7-3.7) and 7.0 months (95%CI: 4.1-9.9) (P=0.024), and the OS were 13.8 months (95%CI: 3.7-23.9) and 20.4 months (95%CI: 12.7-28.1) (P=0.081), respectively.